|
AstraZeneca enters into $232m asthma drug deal with Synairgen
Pharmaceutical Business Review AstraZeneca has entered into a global licence agreement with Synairgen for SNG001, a new, inhaled interferon beta (IFN-beta) being developed for the treatment of respiratory tract viral infections in patients with severe asthma. AstraZeneca … |
View full post on asthma – Google News